Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 12.5 mg and ibuprofen 200 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 12.8 mg and ibuprofen 200 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 15 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 60 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Caffeine 15 mg and codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
3 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
4 |
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 sachet effervescent powder for conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 sachet effervescent powder for conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 60 mg and paracetamol 1 g effervescent powder for oral suspension sachet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 60 mg and paracetamol 1 g effervescent powder for oral suspension sachet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 3 milligram/1 milliliter conventional release oral solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 3 milligram/1 milliliter conventional release oral solution (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 5 mg/mL oral solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 5 mg/mL oral solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 600 microgram/mL oral solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 600 microgram/mL oral solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 60 milligram/1 milliliter conventional release solution for injection ampule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 60 milligram/1 milliliter conventional release solution for injection ampule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 60 mg/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 60 mg/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Brompheniramine maleate 400 microgram/mL and codeine phosphate 2 mg/mL and phenylpropanolamine hydrochloride 2.5 mg/mL oral solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Brompheniramine maleate 400 microgram/mL and codeine phosphate 2 mg/mL and phenylpropanolamine hydrochloride 2.5 mg/mL oral solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 2 mg/mL and promethazine hydrochloride 1.25 mg/mL oral solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 2 mg/mL and promethazine hydrochloride 1.25 mg/mL oral solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 2 mg/mL and phenylephrine hydrochloride 1 mg/mL and promethazine hydrochloride 1.25 mg/mL oral solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate 2 mg/mL and phenylephrine hydrochloride 1 mg/mL and promethazine hydrochloride 1.25 mg/mL oral solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Bromazine hydrochloride 2.5 mg/mL and codeine phosphate 2 mg/mL oral solution |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Bromazine hydrochloride 2.5 mg/mL and codeine phosphate 2 mg/mL oral solution |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 1 milligram/1 milliliter and kaolin 300 milligram/1 milliliter conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 1 milligram/1 milliliter and kaolin 300 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Caffeine 15 mg and codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Caffeine 15 mg and codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Codeine phosphate anhydrous |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Codeine phosphate |
Inferred relationship |
Some |
|
Acetaminophen 500 mg and caffeine 30 mg and codeine phosphate 8 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Acetaminophen 500 mg and caffeine 30 mg and codeine phosphate 8 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Product containing precisely codeine phosphate 15 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 15 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
1 |
Buclizine hydrochloride 6.25 mg and codeine phosphate 8 mg and paracetamol 500 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Buclizine hydrochloride 6.25 mg and codeine phosphate 8 mg and paracetamol 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Product containing precisely caffeine 30 milligram and codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |
Product containing precisely caffeine 30 milligram and codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Codeine phosphate |
Inferred relationship |
Some |
2 |